Literature DB >> 6331480

The influence of naloxone on the circulatory effects of captopril.

P C Rubin, J A Millar, S Sturani, C Lawrie, J L Reid.   

Abstract

The fall in blood pressure produced by captopril is not accompanied by a compensatory tachycardia. Angiotensin converting enzyme may participate in the metabolism of endogenous opioids and these substances can lower blood pressure without reflex tachycardia. It is therefore possible that the hypotensive effect of captopril involves an action on endogenous opioid metabolism. The influence of naloxone, an opiate receptor antagonist, on the cardiovascular effects of captopril has been studied in nine normal volunteers. Mean blood pressure following a 70 degrees head up tilt 1.5 h after captopril was significantly lower than following placebo, but the blood pressure following the combination of captopril and naloxone differed from neither the placebo nor the captopril values. Blood pressures (mm Hg) were: placebo 97.7 +/- 5.9; captopril 83.3 +/- 14.2; captopril + naloxone 89.6 +/- 11.8. Heart rate (beats/min) following a 70 degrees head up tilt at 1.5 h was the same on all three treatments: placebo 83.4 +/- 21.1; captopril 83.3 +/- 16.5; captopril + naloxone 83.6 +/- 11.8. Maximum systolic blood pressure achieved during isometric exercise following captopril + naloxone was intermediate between, and did not differ significantly from, pressures obtained on the other two treatment days. We conclude that co-administration of naloxone may attenuate the effect of captopril on blood pressure and that endogenous opioids could be involved in the actions of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331480      PMCID: PMC1463417          DOI: 10.1111/j.1365-2125.1984.tb02408.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.

Authors:  D P Henry; B J Starman; D G Johnson; R H Williams
Journal:  Life Sci       Date:  1975-02-01       Impact factor: 5.037

2.  A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.

Authors:  S G Chiknas
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

3.  The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Authors:  J E Roulston; G A MacGregor
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

4.  Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients.

Authors:  R J Cody; R C Tarazi; E L Bravo; F M Fouad
Journal:  Clin Sci Mol Med       Date:  1978-11

5.  Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung.

Authors:  D W Cushman; H S Cheung
Journal:  Biochem Pharmacol       Date:  1971-07       Impact factor: 5.858

6.  Inhibition of in situ metabolism of [3H](met5)-enkephalin and potentiation of (met5)-enkephalin analgesia by captopril.

Authors:  S M Stine; H Y Yang; E Costa
Journal:  Brain Res       Date:  1980-04-21       Impact factor: 3.252

7.  Effect of naloxone, a specific opioid inhibitor, on blood pressure fall during sleep.

Authors:  P Rubin; T F Blaschke; C Guilleminault
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

8.  Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate.

Authors:  S L Skinner
Journal:  Circ Res       Date:  1967-04       Impact factor: 17.367

9.  Separation of human brain angiotensin-converting enzyme from enkephalin-degrading activity.

Authors:  A Arregui; C M Lee; P C Emson; L L Iversen
Journal:  Eur J Pharmacol       Date:  1979-10-26       Impact factor: 4.432

10.  Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients.

Authors:  J A Millar; B P McGrath; P G Matthews; C I Johnston
Journal:  Clin Sci (Lond)       Date:  1981-07       Impact factor: 6.124

View more
  4 in total

1.  Increase in plasma beta endorphins precedes vasodepressor syncope.

Authors:  A A Ajayi
Journal:  Br Heart J       Date:  1995-05

2.  Inhibitory regulation by co-released peptides of catecholamine secretion by the canine adrenal medulla.

Authors:  J A Critchley; M R MacLean; A Ungar
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

3.  Captopril and opiate antagonism in essential hypertension.

Authors:  A A Ajayi; P C Rubin; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

4.  Naloxone does not antagonize the antihypertensive effect of chronic captopril therapy in hypertensive patients.

Authors:  G P Bernini; A R Lucarini; M S Vivaldi; C Del Corso; M Lenzi; A Salvetti
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.